TY - JOUR
T1 - Novel measures to assess ventricular assist device patient-reported outcomes
T2 - Findings from the MCS A-QOL study
AU - Grady, Kathleen L
AU - Kallen, Michael Anthony
AU - Beiser, David G.
AU - Lindenfeld, Jo Ann
AU - Teuteberg, Jeffrey
AU - Allen, Larry A.
AU - McIlvennan, Colleen K.
AU - Rich, Jonathan D
AU - Yancy, Clyde
AU - Lee, Christopher S.
AU - Denfeld, Quin E.
AU - Kiernan, Michael
AU - Walsh, Mary Norine
AU - Adler, Eric
AU - Ruo, Bernice
AU - Stehlik, Josef
AU - Kirklin, James K.
AU - Bedjeti, Katy
AU - Cella, Dave
AU - Hahn, Elizabeth A
N1 - Funding Information:
This work was sponsored by the National Institutes of Health , National Heart Lung and Blood Institute (NHLBI), Mechanical Circulatory Support: Measures of Adjustment and Quality of Life (MCS A-QOL, [ R01HL130502 ], Grady KL and Hahn EA [co-PIs]).
Funding Information:
Kathleen L. Grady, PhD, RN – NIH (NIA and NHLBI) funding, support for attending conferences (ISHLT, HFSA, STS Intermacs AQO), leadership roles in ISHLT (director Board of Directors, member ISHLT Foundation Board, chair Grants and Awards Committee). Michael A. Kallen, PhD, M PH – none related to this manuscript. David G. Beiser, MD, MS – none related to this manuscript. JoAnn Lindenfeld, MD – consultant to AstraZeneca, Abbott, Alleviant, Boston Scientific, CVRx, Cytokinetics, Edwards Lifesciences, Merck, Medtronic, VWave. Jeffrey Teuteberg, MD – none related to this manuscript. Larry A. Allen, MD – consultant to ACI Clinical, American Heart Association, Boston Scientific, Cytokinetics, Novartis, Quidel, UpToDate. Colleen K. McIlvennan, PhD, DNP, ANP – none related to this manuscript. Jonathan Rich, MD – none related to this manuscript. Clyde Yancy, MD – none related to this manuscript. Christopher S. Lee, PhD, RN – none related to this manuscript. Quin E. Denfeld, PhD, RN – NIH/NINR funding. Michael Kiernan, MD – consultant: Medtronic and Endotronix, Honoraria: Abiomed. Mary Norine Walsh, MD – none related to this manuscript. Eric Adler, MD – consultant Abbott and Medtronic. Bernice Ruo, MD, MAS – none related to this manuscript. Josef Stehlik, MD – consulting: Medtronic, TransMedics, Natera; grant support: Natera, Merck. James K. Kirklin, MD – none related to this manuscript. Katy Bedjeti, MSW – none related to this manuscript. Dave Cella, PhD – President, PROMIS Health Organization (nonprofit organization, unfunded). Elizabeth A. Hahn, MA – none related to this manuscript.
Publisher Copyright:
© 2023 International Society for the Heart and Lung Transplantation
PY - 2024/1
Y1 - 2024/1
N2 - Background: Generic and heart failure-specific measures do not capture unique aspects of living with a ventricular assist device (VAD). Using state-of-the-science psychometric measurement methods, we developed a measurement system to assess post-ventricular assist device adjustment and health-related quality of life (HRQOL). Methods: Patients were recruited from 10/26/16-2/29/20 from 12 U.S. VAD programs. We created a dataset of participants (n = 620) enrolled before left (L)VAD implantation, with data at 3- or 6- months post-implantation (group1 [n = 154]), and participants enrolled after LVAD implantation, with data at one timepoint (group 2 [n = 466]). We constructed 5 item banks: 3 modified from existing measures and 2 new measures. Analyses included item response theory (IRT) modeling, differential item functioning tests for systematic measurement bias, and indicators of reliability and validity. Results: Of 620 participants, 56% (n = 345) were implanted as destination therapy, 51% (n = 316) were <12 months post-implantation, mean age = 57.3 years, 78% (n = 485) male, 70% (n = 433) White, 58% (n = 353) married/partnered, and 58% (n = 357) with >high school education. We developed 5 new VAD item banks/measures: 6-item VAD Team Communication; 12-item Self-efficacy Regarding VAD Self-care; 11-item Being Bothered by VAD Self-care and Limitations; 7-item Satisfaction with Treatment; and 11-item Stigma. Cronbach's alpha reliability ranged from good (≥0.80) to excellent (≥0.90) for item banks/measures. All measures, except VAD Team Communication, demonstrated at least moderate correlations (≥0.30) with construct validity indicators. Conclusions: These measures meet IRT modeling assumptions and requirements; scores demonstrate reliability and validity. Use of these measures may assist VAD clinicians to inform patients about VADs as a treatment option and guide post-VAD interventions.
AB - Background: Generic and heart failure-specific measures do not capture unique aspects of living with a ventricular assist device (VAD). Using state-of-the-science psychometric measurement methods, we developed a measurement system to assess post-ventricular assist device adjustment and health-related quality of life (HRQOL). Methods: Patients were recruited from 10/26/16-2/29/20 from 12 U.S. VAD programs. We created a dataset of participants (n = 620) enrolled before left (L)VAD implantation, with data at 3- or 6- months post-implantation (group1 [n = 154]), and participants enrolled after LVAD implantation, with data at one timepoint (group 2 [n = 466]). We constructed 5 item banks: 3 modified from existing measures and 2 new measures. Analyses included item response theory (IRT) modeling, differential item functioning tests for systematic measurement bias, and indicators of reliability and validity. Results: Of 620 participants, 56% (n = 345) were implanted as destination therapy, 51% (n = 316) were <12 months post-implantation, mean age = 57.3 years, 78% (n = 485) male, 70% (n = 433) White, 58% (n = 353) married/partnered, and 58% (n = 357) with >high school education. We developed 5 new VAD item banks/measures: 6-item VAD Team Communication; 12-item Self-efficacy Regarding VAD Self-care; 11-item Being Bothered by VAD Self-care and Limitations; 7-item Satisfaction with Treatment; and 11-item Stigma. Cronbach's alpha reliability ranged from good (≥0.80) to excellent (≥0.90) for item banks/measures. All measures, except VAD Team Communication, demonstrated at least moderate correlations (≥0.30) with construct validity indicators. Conclusions: These measures meet IRT modeling assumptions and requirements; scores demonstrate reliability and validity. Use of these measures may assist VAD clinicians to inform patients about VADs as a treatment option and guide post-VAD interventions.
KW - patient-reported outcomes
KW - satisfaction with treatment
KW - self efficacy
KW - stigma
KW - ventricular assist device
UR - http://www.scopus.com/inward/record.url?scp=85171201022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85171201022&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2023.08.007
DO - 10.1016/j.healun.2023.08.007
M3 - Article
C2 - 37591454
AN - SCOPUS:85171201022
SN - 1053-2498
VL - 43
SP - 36
EP - 50
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 1
ER -